VRIJEDNOST KASPAZE 3 U RAZLIKOVANJU ONKOCITOMA OD KROMOFOBNOG KARCINOMA BUBREGA by FRAN ČAKAR & TIHANA REGOVIĆ DŽOMBETA
11
Original PaperActa Med Croatica, 74 (2020) 11-15
THE VALUE OF CASPASE 3 IN DIFFERENTIATING RENAL 
ONCOCYTOMA FROM CHROMOPHOBE RENAL CELL 
CARCINOMA
FRAN ČAKAR1 and TIHANA REGOVIĆ DŽOMBETA1,2
1University of Zagreb, School of Medicine, Department of Pathology and 2Sestre milosrdnice University 
Hospital Centre, Ljudevit Jurak Department of Pathology and Cytology, Zagreb, Croatia
Aim: Renal oncocytoma (RO) and chromophobe renal cell carcinoma (ChRCC) are epithelial neoplasms of the kidney 
with overlapping histologic features, making their differential diagnosis one of the pitfalls in renal pathology. The aim 
of this study was to assess the level of caspase 3 expression in RO and ChRCC, in order to investigate its potential 
value in their differentiation. Methods: The study included 24 RO cases and 24 ChRCC cases, taken from the archives of 
Ljudevit Jurak Department of Pathology and Cytology, Sestre milosrdnice University Hospital Centre Zagreb. The results 
of immunohistochemical analysis were determined semiquantitatively using immunohistochemical staining index (ISI). 
Statistical analysis was done using Mann-Whitney U test. Results: All samples showed positive immunohistochemical 
reaction for caspase 3, with the majority of RO showing moderate ISI and the majority of ChRCC showing low ISI. Conclusion: 
The use of caspase-3 could favor the diagnosis of RO in cases where the tumor shows strong and diffuse staining. Further 
studies on a larger number of cases are needed to confi rm our results.
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INTRODUCTION
Renal oncocytoma (RO) and chromophobe renal cell 
carcinoma (ChRCC) are epithelial neoplasms of the 
kidney that share many histologic similarities. Diff er-
ential diagnosis between the two is oft en diffi  cult due 
to their overlapping features, making it one of the pit-
falls in renal pathology. 
Oncocytoma is a benign neoplasm of the kidney 
which accounts for 5%-9% of all renal neoplasms (1). 
It can occur over a wide age range, but peaks in the 
seventh decade of life, and is usually found incidental-
ly (2). Grossly, RO is usually unencapsulated and well 
circumscribed. Microscopically, it consists of large, 
uniform cells having abundant eosinophilic cytoplasm 
due to the high number of mitochondria. Th e cells are 
arranged in nested or tubulocystic pattern and embed-
ded in hyalinized or myxoid stroma. 
Chromophobe renal cell carcinoma is in epidemiolog-
ical term very similar to RO; it accounts for 5%-7% of 
all renal carcinomas, occurs over a wide age range but 
peaks in the sixth decade, and is oft en found inciden-
tally (1). It is grossly well circumscribed, usually de-
marcated by a fi brous capsule (3). Microscopically, it 
is typically arranged in solid sheets separated by oft en 
hyalinized vascular septa. Th ere are two types of tumor 
cells, i.e. the large, pale ones with distinct cell mem-
branes, located peripherally within the sheets, and the 
smaller ones with eosinophilic, granular cytoplasm, 
usually located centrally (4). Unlike RO, the cytoplasm 
of ChRCC cells is ultrastructurally crowded with loose 
glycogen deposits and not mitochondria (1). 
A number of studies investigated histologic features, 
the use of colloidal iron, immunohistochemical mark-
ers or ultrastructural characteristics that could poten-
tially be used for diff erentiating these tumors (3-7). 
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Due to the high content of mitochondria in RO, one 
of the potential diff erences could be the expression of 
apoptotic markers such as caspase 3, an endoprotease 
involved in terminal phase of apoptosis, degradation 
of the DNA molecule.
AIM 
Th e aim of this study was to assess the level of caspase 
3 expression in RO and ChRCC, in order to investigate 
its potential value in their diff erentiation.
MATERIALS AND METHODS
Materials
Th e study included 24 RO cases and 24 ChRCC cases 
taken from the archives of Ljudevit Jurak Department 
of Pathology and Cytology, Sestre milosrdnice Univer-
sity Hospital Centre, Zagreb (Figure 1).
Fig. 1. Histologic characteristics of oncocytoma (A, HE x100) 
and chromophobe renal cell carcinoma (B, HE x100).
Oncocytoma cases were diagnosed in 11 female and 
13 male patients aged 46-82 (mean age 65) years. Tu-
mor size ranged from 1.5 to 7 (mean 3.1) cm. 
Th e ChRCC cases were found in 12 female and 12 
male patients aged 26-76 (mean age 52) years. Tumor 
size ranged from 2 to 23 (mean 7.2) cm. Sarcomatoid 
transformation was found and histologically verifi ed 
in 2 ChRCC cases. One patient also had 2 oncocyto-
mas beside ChRCC.
Immunohistochemistry
Immunohistochemical staining was performed using 
standard procedures on a DAKO TechMate Horizon 
automated immunostainer (DAKO, Copenhagen, 
Denmark). Th e pretreatment of sections was per-
formed using Dako PT link (deparaffi  nization, rehy-
dration and epitope retrieval). Aft er blocking the en-
dogenous peroxidase activity by 5-minute incubation 
with 3% hydrogen peroxide, the sections were incu-
bated at room temperature with primary polyclonal 
rabbit antibody against caspase-3 (code ab13847, Ab-
cam, dilution 1:50) for 30 minutes. Th is was followed 
by incubation with the labeled polymer (EnVision 
HRP, DAKO, Dennmark). Color was developed by in-
cubation with 3,3’-diaminobenzidine tetrahydrochlo-
ride and slides were counterstained by hematoxylin. 
Tonsil was used as a positive control.
Th e results of immunohistochemical analysis were 
determined semiquantitatively using immunohisto-
chemical staining index (ISI), obtained by multiplying 
the percentage of positive cells (PPC) and staining in-
tensity (SI), as previously described (8). Th e PPC was 
scored as 0 for no positive cells, 1 for up to 10% posi-
tive cells, 2 for >10%-50% positive cells and 3 for more 
than 50% positive cells, while SI was scored as 0 for 
no staining, 1 for weak staining, 2 for moderate stain-
ing and 3 for strong staining. Th e ISI was labeled as 
follows: 0=zero; 1-3=low; 4-6=moderate; and 9=high. 
Statistical methods
Statistical analysis was done using Mann-Whitney U 
test; p<0.05 was considered to be statistically signifi -
cant. Th e analysis was performed using IBM SPSS Sta-
tistics soft ware version 21.0.
RESULTS
Th e results of immunohistochemical analysis are sum-
marized in Table 1. All samples showed positive im-
munohistochemical reaction for caspase 3, with the 
majority of ROs showing moderate ISI and the major-
ity of ChRCCs showing low ISI. Not a single ChRCC 
showed high ISI, while 6 (25%) RO cases showed high 
ISI. Only 2 (8,3%) RO cases showed low ISI. Figure 2 
shows expression of caspase 3 in RO and ChRCC.
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Table 1
Caspase 3 expression in renal oncocytoma (RO) and 
chromophobe renal cell carcinoma (ChRCC), shown as 
immunohistochemical staining index (ISI)
Negative Low Moderate High












Fig. 2. Immunohistochemical expression of caspase 3 
in renal oncocytoma (RO) and chromophobe renal cell 
carcinoma (ChRCC): (A) microphotograph showing high 
immunohistochemical staining index (ISI 9) in RO tissue 
sample (x100); (B) microphotograph showing moderate 
immunohistochemical staining index (ISI 6) in ChRCC tissue 
sample (x100).
Th e diff erence in immunohistochemical staining in-
dex of caspase 3 between the tumors was statistically 
signifi cant (Mann-Whitney U test; p<0,01). Renal on-
cocytomas showed a mean ISI value of 6,46, while the 
mean ISI in ChRCCs was 3,92. 
Also, we found a statistically signifi cant diff erence be-
tween the age of patients with ROs and ChRCCs, with 
the patients having RO being on average around a de-
cade older than the ones with ChRCC. 
DISCUSSION
Oncocytoma and ChRCC are epithelial tumors 
thought to originate from the intercalated cells of 
collecting ducts of the kidney. Th ey both appear 
more oft en sporadically (around 90% of cases), with 
approximately 10% of the cases occurring as part of 
a syndrome, usually the same one, with the same ge-
netic mutations, such as Birt-Hogg-Dubé syndrome 
and renal oncocytosis (1,9). Owing to their occasional 
coexistence in a sporadic form of hybrid tumors, as 
well as within the aforementioned syndromes, they are 
oft en considered to be the opposite ends of the same 
morphological spectrum (9).
Although there are helpful histologic diff erences be-
tween RO and ChRCC, such as the frequent presence 
of a capsule which tends to be thicker in ChRCC, or the 
presence of ‘raisinoid’, binucleated and multinucleated 
cells usually showing perinuclear halos in ChRCC, 
these are sometimes not enough to confi dently direct 
us towards a fi nal diagnosis (3,5). Another diagnos-
tic method considered to be helpful is electron mi-
croscopy, although it is not suitable for daily practice 
since it is time consuming and expensive, while not 
being specifi c or sensitive enough. Th e ultrastructur-
al analyses show that ROs have more abundant and 
larger mitochondria, with long and lamellar cristae, 
while ChRCCs are characterized by numerous cyto-
plasmic microvesicles with a tendency to perinuclear 
localization and more dispersed mitochondria (6). 
Th e number of mitochondria in ChRCC depends on 
the number of microvesicles, the two being inversely 
proportional (6). 
A number of immunohistochemical markers were 
studied for potential diff erence in expression between 
RO and ChRCC. Cytokeratin 7 is said to be typically 
positive in isolated and scattered cells in RO, whereas 
it should show diff use and strong staining in ChRCC, 
although some studies show that ChRCC can be com-
pletely negative and RO can be positive for it (4,10). A 
number of other markers were studied, among many 
are vimentin, CD10, CD117, EMA, racemase, MOC31, 
MAGE-A3/4 and NY-ESO-1, but none of them proved 
to be consistently positive or negative and thereby they 
are not acceptable for diff erentiation (7, 11-14). 
Caspases are the key eff ectors in the execution of 
apoptosis. Th ey are synthesized as proenzymes, which 
become proteolytically cleaved during apoptosis to 
generate active enzymes. Apart from being present 
in the cytosol, procaspases are also localized in other 
subcellular compartments such as mitochondria (15). 
Owing to the high content of mitochondria present in 
ROs but not ChRCCs, we analyzed the expression of 
caspase 3 in these tumors. We found that both ROs 
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and ChRCCs expressed caspase 3, although the ISI 
was signifi cantly higher in ROs. Th e ISI was high in 
25% of ROs, whereas the majority of ChRCCs had low 
ISI. We think that the stronger and diff use staining for 
caspase 3 in ROs could have resulted from the higher 
content of mitochondria. A study by Kowalewski et 
al. (16) showed diff erent results than ours; they found 
that the level of caspase 3 was signifi cantly higher in 
ChRCCs than in ROs. Th e diff erence between the re-
sults could be a consequence of utilization of diff erent 
clones of antibodies and protocols, as well as diff erent 
scoring systems. Kowalewski et al. also analyzed the 
expression of survivin, which was negative in all cases 
of ChRCC, whereas only 5% of the ROs were positive 
(16). 
Th e importance of diff erentiating RO from ChRCC 
lies in their diff erent biological behavior and hence 
diff erent treatment options. Although both of these 
tumors are most commonly treated by partial or com-
plete nephrectomy, active surveillance could also be 
applied. According to Richard et al. (17), ROs and to 
some extent ChRCCs, can initially be safely followed 
with regular imaging techniques, since their annual 
growth rates are low. Certainly, prior to employment 
of such management, histologic diagnosis must be ob-
tained. 
CONCLUSION
Oncocytoma and ChRCC are tumors with apprecia-
ble histologic overlap but diff erent biological behavior. 
Although many immunohistochemical markers have 
been studied in these tumors, none has proved to be 
specifi c or sensitive enough to diff erentiate them. Th e 
use of caspase 3 could favor the diagnosis of RO in cas-
es where the tumor shows strong and diff use staining. 
Further studies on a larger number of cases are needed 
to confi rm our results. 
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Cilj: Onkocitom bubrega i kromofobni karcinom bubrega su tumori epitelnog podrijetla s preklapajućom histološkom sli-
kom, što čini njihovo razlikovanje jednim od izazova u uropatologiji. Cilj ovog istraživanja bio je procijeniti izraženost 
kaspaze 3 u onkocitomu i kromofobnom karcinomu bubrega u svrhu potencijalne primjene tog imunohistokemijskog bi-
ljega u njihovu razlikovanju. Metode: U istraživanju su analizirana 24 histološki potvrđena uzorka onkocitoma i 24 uzorka 
kromofobnog karcinoma bubrega iz arhiva Kliničkog zavoda za patologiju Ljudevit Jurak, KBC-a Sestre milosrdnice u 
Zagrebu. Imunohistokemijska analiza provedena je semikvantitativno primjenom indeksa imunohistokemijskog bojanja 
(immunohistochemical staining index, ISI). Za statističku analizu primijenjen je Mann-Whitneyjev U test. Rezultati: U svim 
uzorcima bila je prisutna pozitivna imunohistokemijska reakcija na kaspazu 3 pri čemu je većina onkocitoma imala umjeren 
ISI, a većina kromofobnih karcinoma nizak ISI. Zaključak: Kaspaza 3 bi mogla naći svoju primjenu u usmjeravanju dijagnoze 
prema onkocitomu bubrega u slučajevima kada je prisutna jaka i difuzna reakcija tumora na ovaj imunohistokemijski biljeg. 
Unatoč tome, potrebna su daljnja istraživanja na većem broju uzoraka kako bi se potvrdila vrijednost naših rezultata.
Ključne riječi: kaspaza 3, onkocitom bubrega, kromofobni karcinom bubrega, imunohistokemija
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